Rayner has entered into a definitive agreement to acquire Swiss-based This AG, the creator and manufacturer of the Sophi phacoemulsification machines. Now, the company is set to embark on a new chapter by incorporating Sophi's cutting-edge phaco technology into its extensive product portfolio.
Sophi, an acronym for Swiss Ophthalmology Innovation, is recognized for its revolutionary approach to phaco technology, emphasizing mobility, simplicity, and safety within the operating theatre. Boasting advanced features such as triple pump fluidics, active IOP control, clean venturi, day cassette, cable-free power supply, and wireless communication, Sophi presents a state-of-the-art surgical system.
Rayner's CEO, Tim Clover, expressed enthusiasm about the acquisition, stating, "The phaco machine plays a central role in cataract surgery. At Rayner, we aspire to launch the highest quality products, inspired by surgeons and driven by science. Sophi shares this vision, and their machines are truly differentiated with breakthrough technology combined with stunning design which makes them such a good fit for Rayner. I’m excited about their product range today, as well as what we will be planning together for tomorrow."
Thomas Koeppel, Founder and CEO of Sophi, echoed the sentiment, saying, "Sophi was created by viewing things from a completely new perspective; to redefine the requirements of a perfect phaco system by focusing on the point of view of the surgeon and their team. We saw the same philosophy in Rayner and are excited to combine in order to offer Sophi through an expanded commercial team and to accelerate our innovation projects."
The acquisition not only marks Rayner's foray into phaco technology but also enhances its comprehensive range of high-quality products for cataract surgery. Rayner's portfolio will now encompass intraocular lenses (IOLs), ophthalmic viscosurgical devices (OVDs), eye drops, pharmaceuticals, digital tools, and single-use recyclable instruments.
Renowned ophthalmic surgeon Erik L. Mertens, MD, expressed his endorsement of Sophi, stating, "Sophi has been my primary phaco machine for the last 3 years, and I would highly recommend it to fellow high-volume premium cataract and refractive surgeons. I have found its superior fluidics, ease of use, and in-field support from the manufacturer to be highly differentiated."
The acquisition officially closed on January 17, 2024.